Liraglutide: difference between revisions
Diff·revision 15 → 16·18:49, 4 Mar 2025
Difference between revision 15 and revision 16 of Liraglutide. 2 lines changed; the page grew by 237 bytes.
| Revision 15 — 22:43, 12 Feb 2025 LotTraceLuka (talk) add the peptide length to the infobox 4,295 bytes ±0 | Revision 16 — 18:49, 4 Mar 2025 IcodecIndra (talk) close an unbalanced quotation mark 4,532 bytes +237 | ||
|---|---|---|---|
| 35 | The [[LEADER trial|LEADER]] trial randomised 9,340 people with type 2 diabetes and high cardiovascular risk and reported a hazard ratio of 0.87 (95% CI 0.78–0.97) for the primary composite cardiovascular outcome, with a reduction in cardiovascular death. It was among the first trials to establish that an incretin therapy could reduce cardiovascular events rather than merely not increase them.{{r|marso2016}} | 35 | The [[LEADER trial|LEADER]] trial randomised 9,340 people with type 2 diabetes and high cardiovascular risk and reported a hazard ratio of 0.87 (95% CI 0.78–0.97) for the primary composite cardiovascular outcome, with a reduction in cardiovascular death. It was among the first trials to establish that an incretin therapy could reduce cardiovascular events rather than merely not increase them.{{r|marso2016}} |
| 36 | 36 | ||
| + | 37 | Liraglutide is also approved for use in adolescents with type 2 diabetes and, in some jurisdictions, for adolescent obesity — a broader paediatric position than most agents in the class hold, reflecting its longer regulatory history. | |
| + | 38 | ||
| 37 | == References == | 39 | == References == |
| 38 | {{reflist}} | 40 | {{reflist}} |